This is the area where families are most likely to encounter enormous claims, and where the honest position requires more hedging than usual. Both things are true: there is real evidence now, and it is early.
What has actually been tested
Bogenschutz and colleagues ran a small proof-of-concept study in 2015 examining psilocybin-assisted treatment for alcohol dependence. Encouraging, but by design not the sort of study that establishes anything — open-label, small, no control group.
The important one came in 2022, in JAMA Psychiatry: a randomised controlled trial of psilocybin-assisted psychotherapy against placebo for adults with alcohol use disorder, with percentage of heavy drinking days as the primary outcome.
That is a real trial in a serious journal, and it reported a benefit for the psilocybin group.
The limits, stated plainly
It is one trial. Medicine is full of promising single trials that did not replicate. One positive RCT establishes that something is worth studying further, not that it works.
The sample was modest, as early-phase trials are.
Blinding is a genuine problem here, and it is not a technicality. People given a psychedelic generally know. So do the therapists. Expectancy is therefore very difficult to separate from drug effect, in a field where expectancy is known to be powerful.
“Psilocybin-assisted psychotherapy” is not a pill. The trials involve extensive preparation, dosing sessions of many hours with two trained therapists present, and structured integration afterwards. Whatever produced the result, it was not the substance alone.
Participants were carefully screened, excluding people with psychosis risk, certain cardiac conditions and various other factors. The trial population is not the general treatment population.
It remains illegal in most of the United States, outside approved research and specific state programmes. Clinics offering it outside those frameworks are not offering what was studied.
How this should be described
The defensible statement is: early randomised evidence suggests psilocybin- assisted psychotherapy may help some people with alcohol use disorder, in a carefully controlled setting with screening and trained support. It is not established treatment, and it is not available legally in most places.
Anything more confident than that is going beyond the data. Anything dismissive is ignoring a properly conducted randomised trial in a major journal.
Why we mention it at all
Two reasons.
The first is that families ask, and they deserve an accurate answer rather than either enthusiasm or a brush-off. Being able to say precisely what has and has not been shown is more useful than a position.
The second is that this area is a magnet for people selling things. Retreats abroad, unregulated clinics, ceremonies with no screening and no follow-up. Someone who knows what the trials actually involved — the screening, the two therapists, the hours of preparation and integration — is much harder to sell to.
What we would say to a family considering it
Not as a first-line option. For alcohol dependence there are treatments with far more evidence, including medications with meta-analytic support across more than a hundred trials.
Not instead of the things that keep people alive. For opioid use disorder especially, this does not displace buprenorphine or methadone.
Screening is not optional. The exclusions in those trials exist for real reasons.
Beware anything that is not the thing that was studied. A ceremony abroad with no preparation, no screening and no integration is not the protocol that produced the result, whatever it is called.
And be careful about the framing. The most concerning claim in this space is that a single experience resolves the problem. Nothing in the evidence supports that, and the structure that follows any acute intervention is what the outcome literature keeps identifying as decisive.
What the trials actually looked like
Worth describing, because “psilocybin therapy” conjures something quite different from what was studied.
Participants went through several preparatory sessions first — building a relationship with the therapists, discussing intentions, and being told in detail what to expect. That is weeks of work before any drug is administered.
The dosing session itself runs six to eight hours, in a comfortable room, with two trained therapists present throughout. The participant typically lies down with eyeshades and music. The therapists are largely silent and their role is safety and reassurance rather than active therapy.
Then integration sessions afterwards — often several — working through what happened and translating it into something durable.
So the intervention is perhaps thirty to forty hours of structured clinical contact, of which the drug occupies one afternoon. Anyone describing this as “taking mushrooms to cure alcoholism” is describing something that has not been tested.
That structure is also why cost and availability are genuine obstacles even where it is legal. Two clinicians for eight hours is not a scalable model at current staffing levels.
The honest position
This is genuinely interesting, genuinely early, and genuinely being overstated by people with something to sell.
Watching it carefully and telling families the truth about where the evidence stands is the right posture. Building a treatment plan around it today is not — and the same case management questions apply here as anywhere else: what happens afterwards, for how long, and who is responsible.
References
- Bogenschutz MP, Ross S, Bhatt S, et al. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 10.1001/jamapsychiatry.2022.2096
- Bogenschutz MP, Forcehimes AA, Pommy JA, et al. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology. 10.1177/0269881114565144
Read more about Rehab Placement.
